# A Phase I Study of TS-142 in Healthy Participants (Single Doses)

> **NCT04169893** · PHASE1 · COMPLETED · sponsor: **Taisho Pharmaceutical Co., Ltd.** · enrollment: 32 (actual)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** Placebo (fasting)
- **DRUG:** Placebo (feeding)
- **DRUG:** 1 mg of TS-142
- **DRUG:** 3 mg of TS-142
- **DRUG:** 10 mg of TS-142 (fasting)
- **DRUG:** 10 mg of TS-142 (feeding)
- **DRUG:** 30 mg of TS-142

## Key facts

- **NCT ID:** NCT04169893
- **Lead sponsor:** Taisho Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-17
- **Primary completion:** 2016-02-06
- **Final completion:** 2016-02-06
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2025-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04169893

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04169893, "A Phase I Study of TS-142 in Healthy Participants (Single Doses)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04169893. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*